每经记者｜肖芮冬 每经编辑｜赵云 5 月 30 日，市场全天震荡调整，创业板指领跌。截至收盘，沪指跌 0.47% ，深成指跌 0.85% ，创业板指跌 0.96% 。 板块方面，猪肉、创新药、银行、 CRO 等板块涨幅居前，黄金、草甘膦、可控核聚变、人形机器人、环 保设备、消费电子等板块跌幅居前。 再次，从实际走势来看，主要股指的日内低点都出现在上午10点前后，后续跌幅收窄，转为震荡走势； 截至收盘，市场昨日涨幅并未完全回吐，两个交易日仍累计上涨。 全市场超 4100 只个股下跌。沪深两市全天成交额 1.14 万亿元，较上个交易日缩量 462 亿。 昨天刚走出大阳线，今天，5月最后一个交易日，A股就出现回调。如何理解？ 我们认为，这里仍适合以平常心看待，理由有四： 首先，昨日之前，市场普遍对端午节前后行情持谨慎态度，突如其来的大涨反而有些超预期，也稍稍大 家拔高对后市的期待值； 其次，今天市场的回调，一定程度上受到"美国上诉法院暂时恢复实施特朗普政府关税政策"消息的影 响，毕竟其抵消了昨天上涨的部分动因； 最后，拉长到周线、月线维度，市场横盘震荡的趋势没有改变，以这样的状态结束5月行情，进入6月， 市场或迎来 ...

Core Viewpoint - The Chinese medicine sector is experiencing a collective pullback in the A-share market, while the Chinese Medicine ETF (560080) has shown resilience, rising nearly 1% and reaching a new high since January 8 of this year [1] Company News - Huawen Pharmaceutical announced the approval from the Singapore Health Sciences Authority for the registration of its traditional Chinese medicine, Tongxie Ning Granules, for sale in Singapore. This marks the fourth overseas registration for the company, following previous approvals for other products [3] - Tongxie Ning Granules is the first natural plant medicine globally for treating IBS-D, demonstrating significant efficacy and high safety, with the ability to prevent recurrence [3] Industry Insights - Huafu Securities indicates that the pressure from high base numbers in the Chinese medicine sector has cleared in the first quarter, with expectations for gradual improvement in performance from Q2 to Q3 of 2025 due to low valuation and low allocation [4] - The firm identifies three major catalysts for the Chinese medicine industry: 1. Accelerated approval and market entry of innovative Chinese medicines, with 9 new drugs approved in 2023 and an expected increase to 16 in 2024 [6] 2. Anticipated adjustments to the essential drug catalog, which will favor innovative Chinese medicines, with a significant increase in the number of traditional Chinese medicine varieties included [6] 3. A decline in the prices of Chinese medicinal materials and expectations for product price increases, which could enhance performance for companies using these materials [7] Key Indicators - The core indicators for the Chinese medicine sector include flu data and the price index of medicinal materials. The flu cases have returned to normal levels, and the pressure on revenue growth for most companies is expected to ease from Q2 2025 [8] - The price index of medicinal materials has been declining since mid-July 2024, with common materials like Lianqiao and Dangshen also showing price decreases, which may alleviate gross margin pressures for companies in 2025 [8]

5月30日午间涨停分析 智通财经5月30日电，今日午盘全市场共32股涨停，连板股总数13只，22股封板未遂，封板率为59%（不含ST股、退市股）。焦点股方面，市场连板高度压 缩至4连板的华森制药、德邦股份。核电板块跌幅居前，人气股王子新材、尚纬股份、融发核电跌停。 归因: 香港立法会５月２1日三读通过《稳定币条例草 案》。今年年底前,香港稳定币有望正式落地。 | 股票名称 | 板数 | 涨跌幅 | 涨停时间 | | | --- | --- | --- | --- | --- | | 御银股份 002177 | 3天3板 | 10.07% | 09:25 | 数字货币 | | 霍普股份 | ロエリザ | 10 000/ | 00.00 | DIAIA | | 301024 | LALTX | 19.9970 | 07:20 | HVVH | | --- | --- | --- | --- | --- | | 海联毛汇 | 2天2板 | 10.04% | 09:25 | 数字货币 | | 002537 | | | | | | 元隆雅图 | 2天2板 | 9.99% | 09:37 | 数字文创 | | 00287 ...

Core Insights - In 2024, the company expects a decline in both revenue and net profit, with projected figures of 3.898 billion and 392 million respectively, representing year-on-year decreases of 19.86% and 15.58% [1] - The first quarter of 2024 continues to show pressure on performance, with revenue of 878 million, down 35.38% year-on-year, and net profit of 83.41 million, down 38.37% [1] - The decline in first-quarter revenue is primarily attributed to a decrease in sales of the core injection product, Heat Toxicity Ning Injection [1][2] Product Performance - The core injection products have historically driven high growth, with Heat Toxicity Ning Injection sales exceeding 1 billion in 2013, but experiencing significant fluctuations due to policy changes [2] - The 2023 National Medical Insurance Directory allowed for increased sales of Heat Toxicity Ning Injection, reaching 6.077 million units, but sales fell to 4.195 million units in 2024, with inventory levels increasing by 759.11% [2] - Ginkgo Biloba Diterpene Amine Injection has also contributed to revenue growth, but its price dropped significantly after negotiations, limiting its growth potential [3] - The company’s oral liquid product, Jin Zhen Oral Liquid, has shown inconsistent sales performance, with year-on-year changes of 74.81%, -22.67%, and 5.13% from 2022 to 2024 [3] Financial Overview - In the first quarter, the injection product category generated approximately 340 million in revenue, down 36.86% year-on-year [4] - The overall revenue for the company in the first quarter was 867.22 million, with a total revenue decline of 35.79% [7] - The company reported a significant decline in operating cash flow, down 59.9% to 77 million in the first quarter, raising concerns about balancing cash flow health with long-term investments [9] New Product Developments - The company has received approvals for several new traditional Chinese medicine products, but their contribution to overall revenue remains limited, with a 10.34% decline in revenue from granules and powders in 2024 [6] - The company has not disclosed sales figures for the "Scattering Cold and Dampness Granules," a product related to COVID-19 treatment, despite investor inquiries [8]

5月30日，外围不确定性反复，A股早盘震荡走弱，截至9:36，沪指跌0.25%，深证成指跌0.52%，创业板指跌0.63%。 消息面上，北京时间周三早上7:00左右，美国联邦法院裁决叫停特朗普的大部分关税。但仅到周四凌晨3:00左右，美国上诉法院就恢复了关 税。白宫贸易顾问纳瓦罗周四表示，如果特朗普政府最终在围绕其贸易政策的法庭斗争中败诉，政府将寻求通过其他方式征收关税。此外，据 报道，特朗普政府寻求关税计划Plan B，允许150天内征收最高15%的关税。 盘面上，高股息风格护盘，银行、保险、电力等方向活跃；医药股再度走强，中药、创新药方向领涨，华森制药4连板；养殖业板块拉升，巨 星农牧涨停；稳定币概念继续发酵，数字货币、移动支付方向领涨，海联金汇、翠微股份涨停；无人驾驶概念持续活跃，云内动力5连板。下 跌方面，高位股重挫，丽人丽妆、王子新材跌停，板块方面，核电、可控核聚变概念回调，消费电子、半导体、汽车产业链等板块跌幅居前。 展望后市，光大证券研报认为，六月市场时常缺乏明确的主线机会，行情容易陷入存量博弈的板块轮动特征中。在增量资金不足、板块轮动的 背景下，需要流动性支撑的大盘蓝筹股可能面临一定的压力，进 ...

Core Viewpoint - Sichuan Xinhehua Traditional Chinese Medicine Co., Ltd. (referred to as "Xinhehua") has submitted an application for an IPO on the Hong Kong Stock Exchange, with Guangfa Securities (Hong Kong) and Agricultural Bank of China International as sponsors. The company aims to raise funds to expand its production capacity and explore overseas markets [1][10]. Group 1: Company Overview - Xinhehua specializes in the research, production, and sales of traditional Chinese medicine pieces, ranking second in China based on revenue from traditional Chinese medicine products in 2023 [2][3]. - The company has attempted to list on the A-share market multiple times but has not succeeded [2][10]. Group 2: Financial Performance - Xinhehua's revenue for the years 2022, 2023, and 2024 was 780.4 million RMB, 1.146 billion RMB, and 1.249 billion RMB, respectively, with net profits of 77.4 million RMB, 104.6 million RMB, and 89.1 million RMB [3][4]. - The gross profit margin has been declining, with total gross margins of 21.1%, 18.5%, and 17.1% for the years 2022, 2023, and 2024 [5][6]. Group 3: Product and Market Dynamics - A significant portion of Xinhehua's revenue comes from a limited range of products, with the top five products accounting for 26.5% of total annual revenue in 2024 [5]. - The gross profit margin for toxic traditional Chinese medicine pieces decreased from 29.7% in 2022 to 19.1% in 2024, while the margin for ordinary pieces fell from 19.6% to 16.7% during the same period [5][6]. Group 4: Future Plans and Use of Proceeds - The funds raised from the IPO will be used for expanding production capacity, upgrading digital production systems, enhancing sales and marketing activities, establishing overseas sales channels in Vietnam and Malaysia, and strategic investments and potential acquisitions [10].

Core Insights - Weikang Pharmaceutical (维康药业) has been recognized for its strong R&D capabilities and excellent products in the traditional Chinese medicine industry, receiving the "2025 Hongding List VIP Cooperation Enterprise" award at the 2025 Health Industry Pharmaceutical Conference [1] - The company's flagship product, Yinhuang Diban (银黄滴丸), has been included in the "Top 10,000+ Pharmacy Star Products" list, highlighting its market acceptance and clinical efficacy [1] - Weikang is focusing on the secondary development of Yinhuang Diban, with a Phase II clinical trial for recurrent oral ulcers successfully completed and discussions for Phase III trials ongoing [1] Product Development - Yinhuang Diban is composed of honeysuckle and Scutellaria baicalensis extracts, known for its safety and effectiveness in treating various throat and respiratory conditions [1] - The product has received multiple industry accolades, including the top position in the "China Pharmaceutical Brand List" for adult cold medications and a prestigious patent award [1] - The company is also developing a second growth engine centered around broken-spore Ganoderma lucidum powder, leveraging its production advantages from the "Hometown of Chinese Ganoderma" in Longquan, Zhejiang [4] Market Strategy - Weikang is implementing a dual-channel strategy, optimizing both online and offline sales channels, including e-commerce platforms and health product counters [4] - The company plans to expand its product line to include high-value items such as Ganoderma lucidum oil and slices, aiming to tap into the market potential of the Ganoderma series [4] - The company’s mission of "Maintaining Life, Committed to Health" drives its continuous R&D efforts and deepens its presence in the traditional Chinese medicine health sector [4] Future Outlook - The company is expected to enhance its market competitiveness through R&D innovation, technological upgrades, and channel optimization in the growing traditional Chinese medicine health industry [5] - With the iterative upgrades of core products and accelerated commercialization of new products, Weikang is poised to expand its market share and strengthen its profit growth drivers [5]

Core Viewpoint - The company, Pianzaihuang Pharmaceutical Co., Ltd., reported a solid performance in 2024, achieving a consolidated revenue of approximately 10.788 billion yuan, a year-on-year increase of 7.25%, and a net profit attributable to shareholders of about 2.977 billion yuan, up 6.42% from the previous year [4][5][6]. Group 1: Meeting Procedures and Governance - The 2024 Annual General Meeting (AGM) will be held on June 20, 2025, at 09:00, at the Zhangzhou Xiangjiang Hotel [3]. - The meeting will include a verification of the identity of attendees, and shareholders will have the right to speak, inquire, and vote [2][3]. - Voting will be conducted by registered ballot, with each share representing one vote [2][3]. Group 2: Business Performance - The company achieved a consolidated revenue of approximately 10.788 billion yuan in 2024, representing a 7.25% increase year-on-year [4]. - The net profit attributable to shareholders was about 2.977 billion yuan, reflecting a 6.42% increase compared to the previous year [4]. - The company paid approximately 14 billion yuan in cash dividends, accounting for 50.04% of the net profit attributable to shareholders [9]. Group 3: Honors and Recognition - The company was recognized as one of the "Top 100 Enterprises in Comprehensive Competitiveness of Traditional Chinese Medicine Industry" and received multiple awards for its brand value and cultural heritage [5][6]. - The company ranked first in the market capitalization of the traditional Chinese medicine industry, with a market value exceeding 120 billion yuan [6]. - The company received various awards, including the "2023 Golden Bull Most Investment Value Award" and "2024 Top 20 ESG Competitiveness in Chinese Pharmaceutical Listed Companies" [6]. Group 4: Research and Development - The company is focusing on enhancing its independent innovation capabilities, with ongoing clinical research on 14 new drug projects [12][13]. - The company has established partnerships with over 10 academicians for collaborative projects, aiming to accelerate technological breakthroughs [13]. - The company is actively involved in national key research projects, enhancing its research capabilities in traditional Chinese medicine [13][14]. Group 5: Future Plans - The company plans to increase its new drug projects and clinical research initiatives, aiming to launch 2-3 new drug projects in the coming year [21]. - The company will focus on expanding its market presence in traditional medicine channels and new consumer markets [21]. - The company aims to enhance its brand visibility through new media and targeted marketing strategies [21].

Group 1: Economic and Industry Updates - China announced a unilateral visa exemption policy for Saudi Arabia, Oman, Kuwait, and Bahrain, effective from June 9, 2025, to June 8, 2026, allowing ordinary passport holders to enter China for up to 30 days without a visa [1] - The Ministry of Finance reported that from January to April 2025, the total operating revenue of state-owned and state-controlled enterprises was 262,755.0 billion yuan, remaining flat year-on-year, while total profit decreased by 1.7% to 13,491.4 billion yuan [2] - A meeting on semiconductor cooperation between China and the EU emphasized the importance of collaboration in the global semiconductor supply chain, with a commitment to oppose unilateralism and ensure supply chain stability [2] - The National Healthcare Security Administration announced a verification of retail pharmacy pharmacists to ensure compliance with labor contracts and prohibit "hanging certificates" or part-time practices [2] Group 2: Company News - Zhongqi Co. has project approval for chlorantraniliprole but has not yet commenced production [4] - Tongda Electric's stock may be subject to market sentiment risks and irrational speculation [4] - ST Longjin's stock will enter the delisting arrangement period starting June 6 [4] - Yaxing Chemical's subsidiary plans to introduce strategic investors [4] - China Gold's controlling shareholder intends to increase its stake in the company by 168 million to 335 million yuan [4] - ST Huaxi signed a significant contract worth 290 million USD for daily operations [4] - Shantui Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [5] - Hehe Information is also planning to issue H-shares for listing on the Hong Kong Stock Exchange [5] - Debon Logistics stated that the current trends in autonomous logistics vehicles will not impact its performance [5] - ST Jiyuan's stock will be delisted on May 29 [5] - ST United plans to acquire 100% of Runtian Industrial and will resume trading on May 29 [5] - Taiji Industry intends to repurchase shares worth 100 million to 120 million yuan [5] - China Energy Construction's subsidiary won a coal and power project contract worth approximately 145.86 billion yuan [5]

数据显示，2024年，公司营业收入为8.6亿元，同比下降10.11%；归母净利润为0.52亿元，同比下降 35.3%。 费用方面，2022年-2024年公司销售费用分别为5.32亿元、4.38亿元、3.72亿元，销售费用率分别为 48.93%、45.86%、43.34%。同期申万中药分类下的企业销售费用率中位数分别为33.02%、33.39%、 33.33%；算数平均值分别为31.89%、32.22%、31.41%，新天药业销售费用率高于行业整体水平约10个 百分点。 据2024年年报显示，报告期内公司销售费用中的市场开发与推广费显著减少，由2023年的3.04亿元降低 至1.26亿元，但职工薪酬及福利由去年同期的5858.99万元大幅增至2024年的1.95亿元，同比增超 230%。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，一则关于新天药业的举报信在网络中广泛流传。 举报信揭露，新天药业通过"向日葵联盟"APP伪造问卷调查（每例300元）、朵儿互联网医院支付高额 科普文章费用（单篇500元），组织虚假学术会议、超标支付讲课费（单场最高5000元）等方式向医生 行贿，并 ...